A new generation of ADC in the treatment of HER2-positive breast cancer patients reaches phase 3 clinical endpoint

On June 8, 2021, Byondis announced that its new generation of antibody conjugate (ADC) trastuzumab duocarmazine (SYD985) has reached the primary endpoint of progression-free survival (PFS) in the phase 3 clinical study TULIP

Trastuzumab duocarmazine is an ADC that targets HER2

The drug is developed using Byondis’ proprietary duocarmazine linker drug (Linker-drug, LD) technology platform

▲The mechanism of action of Trastuzumab duocarmazine (Image source: Byondis official website)

Breast cancer is the most common cancer in the world and the leading cause of cancer deaths among women in more than 100 countries.

Trastuzumab duocarmazine is currently being studied in multiple clinical trials

Note: The original text has been deleted

Reference materials:

[1] Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer.